Fig. 1From: Real-world evidence on the economic implications of CGRP-mAbs as preventive treatment of migraineHealth economic savings and socioeconomic gains associated with CGRP-mAbsCM Chronic migraine; HFEM High-frequency episodic migraine; LFEM Low-frequency episodic migraine; GDP Gross domestic productBack to article page